https://novapharmanews.com/eu/news/ec-approves-itvisma-onasemnogene-sma-ages-2-plus 2026-07-26T11:11:57.530Z NovaPharmaNews en 2026-07-26T08:10:01.407Z EC Approves Itvisma Gene Therapy for SMA 2+ Itvisma, onasemnogene abeparvovec, Rare Diseases, Neurology https://novapharmanews.com/eu/news/chmp-recommends-lyrokaul-lerodalcibep-cholesterol 2026-07-26T10:51:59.944Z NovaPharmaNews en 2026-07-26T08:10:00.104Z CHMP Backs Lyrokaul Monthly PCSK9 Shot Lyrokaul, lerodalcibep, Cardiology, Metabolic Disorders https://novapharmanews.com/eu/news/ec-approves-tepkinly-epcoritamab-r2-follicular-lymphoma 2026-07-26T11:03:27.618Z NovaPharmaNews en 2026-07-26T08:09:58.847Z EC Approves TEPKINLY Plus R2 for Follicular Lymphoma TEPKINLY, epcoritamab, Oncology, Hematology https://novapharmanews.com/eu/news/chmp-recommends-lynavoy-linerixibat-pbc-pruritus 2026-07-26T12:16:37.686Z NovaPharmaNews en 2026-07-26T08:09:57.507Z CHMP Backs Lynavoy for PBC Itch Lynavoy, linerixibat, Hepatology, Rare Diseases https://novapharmanews.com/eu/news/chmp-recommends-nezglyal-leriglitazone-cerebral-ald 2026-07-26T21:41:37.070Z NovaPharmaNews en 2026-07-26T08:09:55.931Z CHMP Backs Nezglyal for Cerebral ALD in Boys Nezglyal, leriglitazone, Rare Diseases, Neurology https://novapharmanews.com/apac/news/nmpa-accepts-everest-lerochol-pcsk9-bla-china 2026-07-26T11:35:09.246Z NovaPharmaNews en 2026-07-26T08:04:48.544Z NMPA Accepts Everest LEROCHOL PCSK9 BLA LEROCHOL, lerodalcibep, Cardiology, Metabolic Disorders https://novapharmanews.com/uploads/articles/nmpa-accepts-everest-lerochol-pcsk9-bla-china.webp NMPA Accepts Everest LEROCHOL PCSK9 BLA https://novapharmanews.com/apac/news/nmpa-ind-kelun-harbour-skb575-hbm7575-asthma 2026-07-26T08:05:00.760Z NovaPharmaNews en 2026-07-26T08:04:45.532Z NMPA Clears Kelun-Harbour Asthma Bispecific IND SKB575, HBM7575, Respiratory, Immunology https://novapharmanews.com/uploads/articles/nmpa-ind-kelun-harbour-skb575-hbm7575-asthma.webp NMPA Clears Kelun-Harbour Asthma Bispecific IND https://novapharmanews.com/apac/news/neuronata-r-retains-mfds-als-conditional-approval-korea 2026-07-26T23:22:06.019Z NovaPharmaNews en 2026-07-26T08:04:42.479Z Neuronata-R Keeps Korea ALS Conditional Nod Neuronata-R, lenzumestrocel, Rare Diseases, Neurology https://novapharmanews.com/uploads/articles/neuronata-r-retains-mfds-als-conditional-approval-korea.webp Neuronata-R Keeps Korea ALS Conditional Nod https://novapharmanews.com/apac/news/orasis-beska-presbyopia-tga-nda-australia 2026-07-26T20:44:26.832Z NovaPharmaNews en 2026-07-26T08:04:39.707Z Orasis Files BESKA Presbyopia NDA in Australia BESKA, pilocarpine, QLOSI, Ophthalmology https://novapharmanews.com/uploads/articles/orasis-beska-presbyopia-tga-nda-australia.webp Orasis Files BESKA Presbyopia NDA in Australia https://novapharmanews.com/apac/news/hansoh-ris-rez-artemis-008-os-win-sclc-china 2026-07-26T23:25:31.541Z NovaPharmaNews en 2026-07-26T08:04:36.290Z Hansoh Ris-Rez Hits OS Goal in China SCLC Trial risvutatug rezetecan, HS-20093, Ris-Rez, Oncology, Lung Cancer https://novapharmanews.com/uploads/articles/hansoh-ris-rez-artemis-008-os-win-sclc-china.webp Hansoh Ris-Rez Hits OS Goal in China SCLC Trial https://novapharmanews.com/us/news/fda-fast-track-lundbeck-lu-ah69593-narcolepsy 2026-07-26T23:05:37.311Z NovaPharmaNews en 2026-07-26T07:48:54.147Z FDA Fast Tracks Lundbeck Lu AH69593 for Narcolepsy Lu AH69593, Neurology, Sleep Disorders https://novapharmanews.com/uploads/articles/fda-fast-track-lundbeck-lu-ah69593-narcolepsy.webp FDA Fast Tracks Lundbeck Lu AH69593 for Narcolepsy https://novapharmanews.com/us/news/monopar-rolling-nda-alxn1840-wilson-disease 2026-07-26T10:02:39.996Z NovaPharmaNews en 2026-07-26T07:48:50.750Z Monopar Starts Rolling NDA for ALXN1840 Wilson ALXN1840, tiomolibdate choline, Rare Diseases https://novapharmanews.com/uploads/articles/monopar-rolling-nda-alxn1840-wilson-disease.webp Monopar Starts Rolling NDA for ALXN1840 Wilson https://novapharmanews.com/us/news/accord-launches-osvyrti-jubereq-denosumab-biosimilars 2026-07-26T10:44:40.757Z NovaPharmaNews en 2026-07-26T07:48:47.488Z Accord Launches OSVYRTI and JUBEREQ Biosimilars OSVYRTI, JUBEREQ, denosumab-desu, Bone Health, Oncology https://novapharmanews.com/uploads/articles/accord-launches-osvyrti-jubereq-denosumab-biosimilars.webp Accord Launches OSVYRTI and JUBEREQ Biosimilars https://novapharmanews.com/us/news/par-health-launches-first-janumet-xr-generic-us 2026-07-26T10:44:42.793Z NovaPharmaNews en 2026-07-26T07:48:44.541Z Par Health Launches First Janumet XR Generic sitagliptin, metformin, Janumet XR, Diabetes, Metabolic Disorders https://novapharmanews.com/uploads/articles/par-health-launches-first-janumet-xr-generic-us.webp Par Health Launches First Janumet XR Generic https://novapharmanews.com/us/news/fda-approves-tylenol-with-naproxen-otc-combo 2026-07-26T10:44:41.839Z NovaPharmaNews en 2026-07-26T07:48:41.360Z FDA Approves TYLENOL with Naproxen OTC Combo TYLENOL with Naproxen, acetaminophen, naproxen sodium, Pain Management https://novapharmanews.com/uploads/articles/fda-approves-tylenol-with-naproxen-otc-combo.webp FDA Approves TYLENOL with Naproxen OTC Combo https://novapharmanews.com/apac/news/nmpa-approves-orzeyful-oveporexton-narcolepsy-china 2026-07-26T23:02:53.096Z NovaPharmaNews en 2026-07-25T05:50:52.390Z Orzeyful: NMPA Clears First OX2R Agonist for NT1 oveporexton, Orzeyful, Sleep Disorders, Neurology